









Markets
/
Stocks
/
nasdaq-alvo
/

Alvotech SA

ALVO

3.234USD

-0.006-0.19%

Market hours （ET）Quotes delayed by 15 min

976.04MMarket Cap

32.34P/E TTM



Alvotech SA

3.234

-0.006-0.19%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Alvotech SA

Currency: USD Updated: 2026-03-27

Key Insights

Alvotech SA's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 128 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.25.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alvotech SA's Score

Industry at a Glance

Industry Ranking

128 / 391

Overall Ranking

248 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Alvotech SA Highlights

StrengthsRisks

Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 530.64% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 31.10, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 18.18M shares, increasing 0.63% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 73.36K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.47.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

7.250

Target Price

+123.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Alvotech SA is 8.10, ranking 51 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 168.90M, representing a year-over-year increase of 10.14%, while its net profit experienced a year-over-year increase of 62.09%.

Score

Industry at a Glance

Previous score

8.10

Change



Financials

4.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.99

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.45

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Alvotech SA's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Alvotech SA is 5.62, ranking 371 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 31.10, which is 30.92% below the recent high of 40.72 and 150.23% above the recent low of -15.62.

Score

Industry at a Glance

Previous score

5.62

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 128/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Alvotech SA is 7.33, ranking 299 out of 391 in the Biotechnology & Medical Research industry. The average price target is 9.75, with a high of 10.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

7.250

Target Price

+123.77%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Alvotech SA

ALVO

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Alvotech SA is 6.17, ranking 265 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.85 and the support level at 2.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.38

Change

-0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.046

Sell

RSI(14)

29.049

Sell

STOCH(KDJ)(9,3,3)

14.130

Oversold

ATR(14)

0.219

Low Volatility

CCI(14)

-112.995

Sell

Williams %R

92.381

Oversold

TRIX(12,20)

-1.169

Sell

StochRSI(14)

49.210

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

3.190

Buy

MA10

3.429

Sell

MA20

3.638

Sell

MA50

4.362

Sell

MA100

4.743

Sell

MA200

6.665

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Alvotech SA is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 6.93%, representing a quarter-over-quarter decrease of 3.78%. The largest institutional shareholder is The Vanguard, holding a total of 4.49M shares, representing 1.44% of shares outstanding, with 3.69% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Aztiq Pharma Partners SARL

101.15M

-2.49%

Celtic Holdings SCA

90.01M

The Vanguard Group, Inc.

Star Investors

4.35M

+2.70%

Bracebridge Capital, LLC

2.71M

T. Rowe Price International Ltd

1.45M

+4.59%

Littlejohn & Co. LLC

1.32M

Stefnir hf.

1.08M

Davies (Richard John)

1.07M

+1.88%

PointState Capital LP

1.05M

BlackRock Institutional Trust Company, N.A.

627.64K

-6.70%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Alvotech SA is 3.41, ranking 141 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.26. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Alvotech SA’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.